PhagoMed Biopharma is a biotechnology company developing phage therapies to replace ineffective antibiotics that is headquartered in Vienna, Austria and was founded in 2017 by Alexander Belcredi and Burkhard Wippermann.
PM398 is a phage therapy designed to destroy multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA).
On August 28, 2018 PhagoMed Biopharma completed a seed funding round with €4M in funding from from undisclosed investors.
PhagoMed - Virtual Tour (aws Phoenix video in English)
February 13, 2019
PhagoMed Biopharma uses technology to find alternative to antibiotics
January 8, 2019
PhagoMed PM398 in action
November 13, 2018
Dawson SewellWriting about startups.
Katrina-Kay PettittData Duchess @ Golden
Elena RubanFreelancer now. Graduated from Financial University
Meredith HanelMedical Genetics PhD, following life science applications that improve the health of humans and our planet.
Wyckliffe OtienoDedicated information technology enthusiast.
Lax MariappanTechnopreneur, Open source enthusiast, author, speaker. Co-founder of Eternus Global. Crafting applications for the medical industry.
Vlad BotushninuI am a beginner programmer, I study IT sphere and cryptocurrencies
Marie Gabrielle Laguna- BediaCo-founder and Managing Partner of Eternus Global. Physician of internal medicine, app developer and entrepreneur
Neelam JhaveriTechno Geek + Gamer + Fashionista + Sense of Humor = It's ME